Loading…

Modifications of Sarcoplasmic Reticulum Function Prevent Progression of Sarcomere-Linked Hypertrophic Cardiomyopathy Despite a Persistent Increase in Myofilament Calcium Response

Hypertrophic cardiomyopathy (HCM) is a genetic disorder caused by mutations in different genes mainly encoding myofilament proteins and therefore called a "disease of the sarcomere." Despite the discovery of sarcomere protein mutations linked to HCM almost 30 years ago, the cellular mechan...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in physiology 2020-03, Vol.11, p.107-107
Main Authors: Chowdhury, Shamim A K, Warren, Chad M, Simon, Jillian N, Ryba, David M, Batra, Ashley, Varga, Peter, Kranias, Evangelia G, Tardiff, Jil C, Solaro, R John, Wolska, Beata M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c462t-e1d53f9d8ea53cda3acbacda7cc95c1eedc6539fb73c826439f76a0b53976cf63
cites cdi_FETCH-LOGICAL-c462t-e1d53f9d8ea53cda3acbacda7cc95c1eedc6539fb73c826439f76a0b53976cf63
container_end_page 107
container_issue
container_start_page 107
container_title Frontiers in physiology
container_volume 11
creator Chowdhury, Shamim A K
Warren, Chad M
Simon, Jillian N
Ryba, David M
Batra, Ashley
Varga, Peter
Kranias, Evangelia G
Tardiff, Jil C
Solaro, R John
Wolska, Beata M
description Hypertrophic cardiomyopathy (HCM) is a genetic disorder caused by mutations in different genes mainly encoding myofilament proteins and therefore called a "disease of the sarcomere." Despite the discovery of sarcomere protein mutations linked to HCM almost 30 years ago, the cellular mechanisms responsible for the development of this disease are not completely understood and likely vary among different mutations. Moreover, despite many efforts to develop effective treatments for HCM, these have largely been unsuccessful, and more studies are needed to better understand the cellular mechanisms of the disease. In experiments reported here, we investigated a mouse model expressing the mutant cTnT-R92Q, which is linked to HCM and induces an increase in myofilament Ca sensitivity and diastolic dysfunction. We found that early correction of the diastolic dysfunction by phospholamban knockout (PLNKO) was able to prevent the development of the HCM phenotype in troponin T (TnT)-R92Q transgenic (TG) mice. Four groups of mice in FVB/N background were generated and used for the experiments: (1) non-transgenic (NTG)/PLN mice, which express wild-type TnT and normal level of PLN; (2) NTG/PLNKO mice, which express wild-type TnT and no PLN; (3) TG/PLN mice, which express TnT-R92Q and normal level of PLN; (4) TG/PLNKO mice, which express TnT-R92Q and no PLN. Cardiac function was determined using both standard echocardiographic parameters and speckle tracking strain measurements. We found that both atrial morphology and diastolic function were altered in TG/PLN mice but normal in TG/PLNKO mice. Histological analysis showed a disarray of myocytes and increased collagen deposition only in TG/PLN hearts. We also observed increased Ca /calmodulin-dependent protein kinase II (CaMKII) phosphorylation only in TG/PLN hearts but not in TG/PLNKO hearts. The rescue of the HCM phenotype was not associated with differences in myofilament Ca sensitivity between TG/PLN and TG/PLNKO mice. Moreover, compared to standard systolic echo parameters, such as ejection fraction (EF), speckle strain measurements provided a more sensitive approach to detect early systolic dysfunction in TG/PLN mice. In summary, our results indicate that targeting diastolic dysfunction through altering Ca fluxes with no change in myofilament response to Ca was able to prevent the development of the HCM phenotype and should be considered as a potential additional treatment for HCM patients.
doi_str_mv 10.3389/fphys.2020.00107
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4f5f102bf0564eda9c95446b3789c405</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4f5f102bf0564eda9c95446b3789c405</doaj_id><sourcerecordid>2383517187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-e1d53f9d8ea53cda3acbacda7cc95c1eedc6539fb73c826439f76a0b53976cf63</originalsourceid><addsrcrecordid>eNpVUk1v1DAQjRCIVqV3TshHLlns2M7HBQktLV1pK6oCEjdr4ox3XZI42Eml_C1-Ic5uW7W-zOj5vTdj6yXJe0ZXnJfVJzPs57DKaEZXlDJavEpOWZ6LlIrs9-tn_UlyHsIdjUdELmVvkxOeZYyWnJ4m_65dY43VMFrXB-IM-QFeu6GF0FlNbnG0emqnjlxOvV445MbjPfZjrG7nMYQFe5R16DHd2v4PNuRqHtCP3g376LMG31jXzW6AcT-TrxgGOyIBcoM-2DAuhptee4SAxPbkenbGttAt-BpabeMGt1EUd8R3yRsDbcDzh3qW_Lq8-Lm-Srffv23WX7apFnk2psgayU3VlAiS6wY46BpiLbSupGaIjc4lr0xdcF1muYhtkQOtI1bk2uT8LNkcfRsHd2rwtgM_KwdWHQDndwp8_J4WlTDSMJrVhspcYANVHCFEXvOirLSgMnp9PnoNU93FyfFdHtoXpi9vertXO3evClrIUpbR4OODgXd_Jwyj6mzQ2LbQo5uCynjJJStYWUQqPVK1dyF4NE9jGFVLctQhOWpJjjokJ0o-PF_vSfCYE_4fsEjHHQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2383517187</pqid></control><display><type>article</type><title>Modifications of Sarcoplasmic Reticulum Function Prevent Progression of Sarcomere-Linked Hypertrophic Cardiomyopathy Despite a Persistent Increase in Myofilament Calcium Response</title><source>PubMed Central</source><creator>Chowdhury, Shamim A K ; Warren, Chad M ; Simon, Jillian N ; Ryba, David M ; Batra, Ashley ; Varga, Peter ; Kranias, Evangelia G ; Tardiff, Jil C ; Solaro, R John ; Wolska, Beata M</creator><creatorcontrib>Chowdhury, Shamim A K ; Warren, Chad M ; Simon, Jillian N ; Ryba, David M ; Batra, Ashley ; Varga, Peter ; Kranias, Evangelia G ; Tardiff, Jil C ; Solaro, R John ; Wolska, Beata M</creatorcontrib><description>Hypertrophic cardiomyopathy (HCM) is a genetic disorder caused by mutations in different genes mainly encoding myofilament proteins and therefore called a "disease of the sarcomere." Despite the discovery of sarcomere protein mutations linked to HCM almost 30 years ago, the cellular mechanisms responsible for the development of this disease are not completely understood and likely vary among different mutations. Moreover, despite many efforts to develop effective treatments for HCM, these have largely been unsuccessful, and more studies are needed to better understand the cellular mechanisms of the disease. In experiments reported here, we investigated a mouse model expressing the mutant cTnT-R92Q, which is linked to HCM and induces an increase in myofilament Ca sensitivity and diastolic dysfunction. We found that early correction of the diastolic dysfunction by phospholamban knockout (PLNKO) was able to prevent the development of the HCM phenotype in troponin T (TnT)-R92Q transgenic (TG) mice. Four groups of mice in FVB/N background were generated and used for the experiments: (1) non-transgenic (NTG)/PLN mice, which express wild-type TnT and normal level of PLN; (2) NTG/PLNKO mice, which express wild-type TnT and no PLN; (3) TG/PLN mice, which express TnT-R92Q and normal level of PLN; (4) TG/PLNKO mice, which express TnT-R92Q and no PLN. Cardiac function was determined using both standard echocardiographic parameters and speckle tracking strain measurements. We found that both atrial morphology and diastolic function were altered in TG/PLN mice but normal in TG/PLNKO mice. Histological analysis showed a disarray of myocytes and increased collagen deposition only in TG/PLN hearts. We also observed increased Ca /calmodulin-dependent protein kinase II (CaMKII) phosphorylation only in TG/PLN hearts but not in TG/PLNKO hearts. The rescue of the HCM phenotype was not associated with differences in myofilament Ca sensitivity between TG/PLN and TG/PLNKO mice. Moreover, compared to standard systolic echo parameters, such as ejection fraction (EF), speckle strain measurements provided a more sensitive approach to detect early systolic dysfunction in TG/PLN mice. In summary, our results indicate that targeting diastolic dysfunction through altering Ca fluxes with no change in myofilament response to Ca was able to prevent the development of the HCM phenotype and should be considered as a potential additional treatment for HCM patients.</description><identifier>ISSN: 1664-042X</identifier><identifier>EISSN: 1664-042X</identifier><identifier>DOI: 10.3389/fphys.2020.00107</identifier><identifier>PMID: 32210830</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Ca2+/calmodulin-dependent protein kinase II (CaMKII) ; hypertrophic cardiomyopathy ; myofilament Ca2+ sensitivity ; phospholamban ; Physiology ; speckle strain ; troponin T (TnT)</subject><ispartof>Frontiers in physiology, 2020-03, Vol.11, p.107-107</ispartof><rights>Copyright © 2020 Chowdhury, Warren, Simon, Ryba, Batra, Varga, Kranias, Tardiff, Solaro and Wolska.</rights><rights>Copyright © 2020 Chowdhury, Warren, Simon, Ryba, Batra, Varga, Kranias, Tardiff, Solaro and Wolska. 2020 Chowdhury, Warren, Simon, Ryba, Batra, Varga, Kranias, Tardiff, Solaro and Wolska</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-e1d53f9d8ea53cda3acbacda7cc95c1eedc6539fb73c826439f76a0b53976cf63</citedby><cites>FETCH-LOGICAL-c462t-e1d53f9d8ea53cda3acbacda7cc95c1eedc6539fb73c826439f76a0b53976cf63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075858/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075858/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32210830$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chowdhury, Shamim A K</creatorcontrib><creatorcontrib>Warren, Chad M</creatorcontrib><creatorcontrib>Simon, Jillian N</creatorcontrib><creatorcontrib>Ryba, David M</creatorcontrib><creatorcontrib>Batra, Ashley</creatorcontrib><creatorcontrib>Varga, Peter</creatorcontrib><creatorcontrib>Kranias, Evangelia G</creatorcontrib><creatorcontrib>Tardiff, Jil C</creatorcontrib><creatorcontrib>Solaro, R John</creatorcontrib><creatorcontrib>Wolska, Beata M</creatorcontrib><title>Modifications of Sarcoplasmic Reticulum Function Prevent Progression of Sarcomere-Linked Hypertrophic Cardiomyopathy Despite a Persistent Increase in Myofilament Calcium Response</title><title>Frontiers in physiology</title><addtitle>Front Physiol</addtitle><description>Hypertrophic cardiomyopathy (HCM) is a genetic disorder caused by mutations in different genes mainly encoding myofilament proteins and therefore called a "disease of the sarcomere." Despite the discovery of sarcomere protein mutations linked to HCM almost 30 years ago, the cellular mechanisms responsible for the development of this disease are not completely understood and likely vary among different mutations. Moreover, despite many efforts to develop effective treatments for HCM, these have largely been unsuccessful, and more studies are needed to better understand the cellular mechanisms of the disease. In experiments reported here, we investigated a mouse model expressing the mutant cTnT-R92Q, which is linked to HCM and induces an increase in myofilament Ca sensitivity and diastolic dysfunction. We found that early correction of the diastolic dysfunction by phospholamban knockout (PLNKO) was able to prevent the development of the HCM phenotype in troponin T (TnT)-R92Q transgenic (TG) mice. Four groups of mice in FVB/N background were generated and used for the experiments: (1) non-transgenic (NTG)/PLN mice, which express wild-type TnT and normal level of PLN; (2) NTG/PLNKO mice, which express wild-type TnT and no PLN; (3) TG/PLN mice, which express TnT-R92Q and normal level of PLN; (4) TG/PLNKO mice, which express TnT-R92Q and no PLN. Cardiac function was determined using both standard echocardiographic parameters and speckle tracking strain measurements. We found that both atrial morphology and diastolic function were altered in TG/PLN mice but normal in TG/PLNKO mice. Histological analysis showed a disarray of myocytes and increased collagen deposition only in TG/PLN hearts. We also observed increased Ca /calmodulin-dependent protein kinase II (CaMKII) phosphorylation only in TG/PLN hearts but not in TG/PLNKO hearts. The rescue of the HCM phenotype was not associated with differences in myofilament Ca sensitivity between TG/PLN and TG/PLNKO mice. Moreover, compared to standard systolic echo parameters, such as ejection fraction (EF), speckle strain measurements provided a more sensitive approach to detect early systolic dysfunction in TG/PLN mice. In summary, our results indicate that targeting diastolic dysfunction through altering Ca fluxes with no change in myofilament response to Ca was able to prevent the development of the HCM phenotype and should be considered as a potential additional treatment for HCM patients.</description><subject>Ca2+/calmodulin-dependent protein kinase II (CaMKII)</subject><subject>hypertrophic cardiomyopathy</subject><subject>myofilament Ca2+ sensitivity</subject><subject>phospholamban</subject><subject>Physiology</subject><subject>speckle strain</subject><subject>troponin T (TnT)</subject><issn>1664-042X</issn><issn>1664-042X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUk1v1DAQjRCIVqV3TshHLlns2M7HBQktLV1pK6oCEjdr4ox3XZI42Eml_C1-Ic5uW7W-zOj5vTdj6yXJe0ZXnJfVJzPs57DKaEZXlDJavEpOWZ6LlIrs9-tn_UlyHsIdjUdELmVvkxOeZYyWnJ4m_65dY43VMFrXB-IM-QFeu6GF0FlNbnG0emqnjlxOvV445MbjPfZjrG7nMYQFe5R16DHd2v4PNuRqHtCP3g376LMG31jXzW6AcT-TrxgGOyIBcoM-2DAuhptee4SAxPbkenbGttAt-BpabeMGt1EUd8R3yRsDbcDzh3qW_Lq8-Lm-Srffv23WX7apFnk2psgayU3VlAiS6wY46BpiLbSupGaIjc4lr0xdcF1muYhtkQOtI1bk2uT8LNkcfRsHd2rwtgM_KwdWHQDndwp8_J4WlTDSMJrVhspcYANVHCFEXvOirLSgMnp9PnoNU93FyfFdHtoXpi9vertXO3evClrIUpbR4OODgXd_Jwyj6mzQ2LbQo5uCynjJJStYWUQqPVK1dyF4NE9jGFVLctQhOWpJjjokJ0o-PF_vSfCYE_4fsEjHHQ</recordid><startdate>20200310</startdate><enddate>20200310</enddate><creator>Chowdhury, Shamim A K</creator><creator>Warren, Chad M</creator><creator>Simon, Jillian N</creator><creator>Ryba, David M</creator><creator>Batra, Ashley</creator><creator>Varga, Peter</creator><creator>Kranias, Evangelia G</creator><creator>Tardiff, Jil C</creator><creator>Solaro, R John</creator><creator>Wolska, Beata M</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200310</creationdate><title>Modifications of Sarcoplasmic Reticulum Function Prevent Progression of Sarcomere-Linked Hypertrophic Cardiomyopathy Despite a Persistent Increase in Myofilament Calcium Response</title><author>Chowdhury, Shamim A K ; Warren, Chad M ; Simon, Jillian N ; Ryba, David M ; Batra, Ashley ; Varga, Peter ; Kranias, Evangelia G ; Tardiff, Jil C ; Solaro, R John ; Wolska, Beata M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-e1d53f9d8ea53cda3acbacda7cc95c1eedc6539fb73c826439f76a0b53976cf63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Ca2+/calmodulin-dependent protein kinase II (CaMKII)</topic><topic>hypertrophic cardiomyopathy</topic><topic>myofilament Ca2+ sensitivity</topic><topic>phospholamban</topic><topic>Physiology</topic><topic>speckle strain</topic><topic>troponin T (TnT)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chowdhury, Shamim A K</creatorcontrib><creatorcontrib>Warren, Chad M</creatorcontrib><creatorcontrib>Simon, Jillian N</creatorcontrib><creatorcontrib>Ryba, David M</creatorcontrib><creatorcontrib>Batra, Ashley</creatorcontrib><creatorcontrib>Varga, Peter</creatorcontrib><creatorcontrib>Kranias, Evangelia G</creatorcontrib><creatorcontrib>Tardiff, Jil C</creatorcontrib><creatorcontrib>Solaro, R John</creatorcontrib><creatorcontrib>Wolska, Beata M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chowdhury, Shamim A K</au><au>Warren, Chad M</au><au>Simon, Jillian N</au><au>Ryba, David M</au><au>Batra, Ashley</au><au>Varga, Peter</au><au>Kranias, Evangelia G</au><au>Tardiff, Jil C</au><au>Solaro, R John</au><au>Wolska, Beata M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modifications of Sarcoplasmic Reticulum Function Prevent Progression of Sarcomere-Linked Hypertrophic Cardiomyopathy Despite a Persistent Increase in Myofilament Calcium Response</atitle><jtitle>Frontiers in physiology</jtitle><addtitle>Front Physiol</addtitle><date>2020-03-10</date><risdate>2020</risdate><volume>11</volume><spage>107</spage><epage>107</epage><pages>107-107</pages><issn>1664-042X</issn><eissn>1664-042X</eissn><abstract>Hypertrophic cardiomyopathy (HCM) is a genetic disorder caused by mutations in different genes mainly encoding myofilament proteins and therefore called a "disease of the sarcomere." Despite the discovery of sarcomere protein mutations linked to HCM almost 30 years ago, the cellular mechanisms responsible for the development of this disease are not completely understood and likely vary among different mutations. Moreover, despite many efforts to develop effective treatments for HCM, these have largely been unsuccessful, and more studies are needed to better understand the cellular mechanisms of the disease. In experiments reported here, we investigated a mouse model expressing the mutant cTnT-R92Q, which is linked to HCM and induces an increase in myofilament Ca sensitivity and diastolic dysfunction. We found that early correction of the diastolic dysfunction by phospholamban knockout (PLNKO) was able to prevent the development of the HCM phenotype in troponin T (TnT)-R92Q transgenic (TG) mice. Four groups of mice in FVB/N background were generated and used for the experiments: (1) non-transgenic (NTG)/PLN mice, which express wild-type TnT and normal level of PLN; (2) NTG/PLNKO mice, which express wild-type TnT and no PLN; (3) TG/PLN mice, which express TnT-R92Q and normal level of PLN; (4) TG/PLNKO mice, which express TnT-R92Q and no PLN. Cardiac function was determined using both standard echocardiographic parameters and speckle tracking strain measurements. We found that both atrial morphology and diastolic function were altered in TG/PLN mice but normal in TG/PLNKO mice. Histological analysis showed a disarray of myocytes and increased collagen deposition only in TG/PLN hearts. We also observed increased Ca /calmodulin-dependent protein kinase II (CaMKII) phosphorylation only in TG/PLN hearts but not in TG/PLNKO hearts. The rescue of the HCM phenotype was not associated with differences in myofilament Ca sensitivity between TG/PLN and TG/PLNKO mice. Moreover, compared to standard systolic echo parameters, such as ejection fraction (EF), speckle strain measurements provided a more sensitive approach to detect early systolic dysfunction in TG/PLN mice. In summary, our results indicate that targeting diastolic dysfunction through altering Ca fluxes with no change in myofilament response to Ca was able to prevent the development of the HCM phenotype and should be considered as a potential additional treatment for HCM patients.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>32210830</pmid><doi>10.3389/fphys.2020.00107</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-042X
ispartof Frontiers in physiology, 2020-03, Vol.11, p.107-107
issn 1664-042X
1664-042X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_4f5f102bf0564eda9c95446b3789c405
source PubMed Central
subjects Ca2+/calmodulin-dependent protein kinase II (CaMKII)
hypertrophic cardiomyopathy
myofilament Ca2+ sensitivity
phospholamban
Physiology
speckle strain
troponin T (TnT)
title Modifications of Sarcoplasmic Reticulum Function Prevent Progression of Sarcomere-Linked Hypertrophic Cardiomyopathy Despite a Persistent Increase in Myofilament Calcium Response
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T07%3A14%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modifications%20of%20Sarcoplasmic%20Reticulum%20Function%20Prevent%20Progression%20of%20Sarcomere-Linked%20Hypertrophic%20Cardiomyopathy%20Despite%20a%20Persistent%20Increase%20in%20Myofilament%20Calcium%20Response&rft.jtitle=Frontiers%20in%20physiology&rft.au=Chowdhury,%20Shamim%20A%20K&rft.date=2020-03-10&rft.volume=11&rft.spage=107&rft.epage=107&rft.pages=107-107&rft.issn=1664-042X&rft.eissn=1664-042X&rft_id=info:doi/10.3389/fphys.2020.00107&rft_dat=%3Cproquest_doaj_%3E2383517187%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-e1d53f9d8ea53cda3acbacda7cc95c1eedc6539fb73c826439f76a0b53976cf63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2383517187&rft_id=info:pmid/32210830&rfr_iscdi=true